Moreover, the success of bevacizumab, a VEGF antibody, in combination with atezolizumab, a PD-L1 inhibitor, for the treatment of advanced HCC highlights the potential role of these immune players in the treatment of HCC [116]. This evidence concerns the gene VEGFA and hepatocellular carcinoma.